Amylyx Pharmaceuticals
AMLX
AMLX
165 hedge funds and large institutions have $1.49B invested in Amylyx Pharmaceuticals in 2025 Q3 according to their latest regulatory filings, with 54 funds opening new positions, 44 increasing their positions, 48 reducing their positions, and 19 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more capital invested
Capital invested by funds: $ → $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding in top 10
Funds holding in top 10: →
31.41% more ownership
Funds ownership: 91.64% → 123.05% (+31%)
27% more funds holding
Funds holding: 130 → 165 (+35)
8% less repeat investments, than reductions
Existing positions increased: 44 | Existing positions reduced: 48
Holders
165
Holding in Top 10
9
Calls
$7.31M
Puts
$2.15M
Top Buyers
| 1 | +$113M | |
| 2 | +$55.4M | |
| 3 | +$45.6M | |
| 4 |
Janus Henderson Group
London,
United Kingdom
|
+$34.5M |
| 5 |
PBA
Paradigm Biocapital Advisors
New York
|
+$25.8M |
Top Sellers
| 1 | -$27.2M | |
| 2 | -$27M | |
| 3 | -$23.7M | |
| 4 |
Millennium Management
New York
|
-$14.9M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$13.7M |
